The newest Phase 3 TRIUMPH-4 data showed average weight loss of 28.7% at doses of 9 to 12 mg over 68 weeks
A 4 mg maintenance dose, stepped down after the primary weight-loss phase, is aimed at the real-world question of how to hold a 25-28% loss over years without keeping participants on a dose level that many cannot tolerate indefinitely
Clinical trials for tirzepatide in the SURMOUNT program found mean weight reductions approaching 20.9% at the highest tested dose over 72 weeks
District Court in New York unsealed a March 2025 complaint filed by Gilead Sciences against a pharmacy in Queens, New York alleged to have sold counterfeit Biktarvy, an HIV treatment, and refused to disclose its source
Lawsuits against Novo Nordisk, the pharmaceutical giant behind Ozempic, continue to mount as more individuals report severe side effects from the drug
Choose Medisafe or MyTherapy for generic medication reminders unrelated to GLP-1